Probi announces new representative for Blis Board

20 December 2022
Probi announces new representative for Blis Board
Blis Technologies Limited (NZX:BLT) advises the appointment of Dr Jörn Andreas as a director of the
company with effect from 1 January 2023. Dr Andreas will replace Tom Rönnlund who is retiring
from the board following stepping down as CEO of Probi AB earlier this month.

Dr Andreas has been a director of Probi AB since 2019 and is CEO of the Cosmetic Ingredients
Division at Symrise . He also has experience from both a previous assignment as board member
(2014-2016) at Probi and his position as CFO of the company (2017-2018).

He has extensive international experience working at Symrise in France and USA in different finance
and general management roles. Jörn has also worked for The Boston Consulting Group and Bayer AG
in Germany.

The board has determined that Dr Andreas is not an independent director due to his role as a
director of Probi AB, which is a substantial product holder of Blis Technologies. Dr Andreas will
formally offer himself for re-election as director at the 2023 shareholders’ meeting.

Chairman Geoff Plunket said “We are delighted to have Jörn joining the board. Jörn has extensive
commercial experience in senior executive and board roles that will complement our refocused
strategy. His experience with both Probi and Symrise provides insight across a significant cross
section of ingredient markets globally.”

I also wish to acknowledge the contribution Tom has made during his time on the board. He has
provided valuable insights into the probiotic market and been pivotal in his role as Probi CEO in
establishing a strong working relationship between the Blis and Probi teams.


Ends

For further information, please contact:

Geoff Plunket
Chair
+64 21 229 8886

About Blis Technologies Ltd

Delivering proven health benefits through evidence-based, advanced probiotics
Blis Technologies is an NZX-listed manufacturer of advanced probiotic strains that go beyond the gut.
Combining innovation with evidence-based research and the highest quality production controls enables
the delivery of probiotic solutions for specific health targets including throat health, halitosis (bad breath),
immune support, teeth and gum health and skin health. BLIS® products are sold throughout New Zealand
and in Asia, Europe and the USA. More information about Blis Technologies Ltd can be found at
www.blis.co.nz.